Complimenting Traditional Research With Genomic Data in Urology
In this video interview, Sujay Jadhav, CEO of Verana Health, discusses how using genomic data and real-world evidence can provide added context to traditional factors such as Gleason scores and PSA levels.
In a recent video interview with Applied Clinical Trials, Sujay Jadhav, CEO of Verana Health, discussed potential advancements the clinical research industry could see in 2025. Jadhav highlighted how unstructured data like physician notes and imaging data can be leveraged to improve disease identification and progression tracking. He also talked synthetic control arms and how they can replace expensive non-treatment arms, enhancing trial efficiency.
ACT: Can you share some examples of therapeutic areas that will benefit the most from advancements in real-world evidence (RWE)? What will its impact be in these areas?
Jadhav: I think there's a number of areas and examples that we're seeing in our therapeutic areas that we focus on with real-world evidence. One is in the urology space around prostate cancer care and leveraging not just taking data that is available from EHR data, but also genomic data as well. Historically, when you look at prostate cancer, a lot of the reliance has been on traditional factors such as Gleason scores and PSA levels. Sometimes this results in overall under treatment of that particular disease, but I think complementing that with real-world data and genomic data, I think it can lead to better diagnosis of this and better understanding of the patient journey as well, and then allow you to tailor the treatment decisions and help improve recruitment with the overall clinical trial process. We’re seeing that actually play out quite a bit in the prostate cancer arena.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
